Sage Therapeutics jumped almost 6% to close at $85.04 on Feb.
Sage Therapeutics (SAGE) has announced a massive restructuring that appears to abandon the launch of post-partum depression drug Zulresso. “Zulresso is a hospital-based …
Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.
Experienced investors in search of growth know to look beyond current trends and market momentum or rely on pundit’s expectations. Today’s results are …
Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.
